RT Journal Article
T1 Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry.
A1 Kapelios, Chris J
A1 Laroche, Cécile
A1 Crespo-Leiro, Maria G
A1 Anker, Stefan D
A1 Coats, Andrew J S
A1 Díaz-Molina, Beatria
A1 Filippatos, Gerasimos
A1 Lainscak, Mitja
A1 Maggioni, Aldo P
A1 McDonagh, Theresa
A1 Mebazaa, Alexandre
A1 Metra, Marco
A1 Moura, Brenda
A1 Mullens, Wilfried
A1 Piepoli, Massimo F
A1 Rosano, Giuseppe M C
A1 Ruschitzka, Frank
A1 Seferovic, Petar M
A1 Lund, Lars H
A1 Heart Failure Long-Term Registry Investigators Group, 
K1 Chronic heart failure
K1 Drug titration
K1 Furosemide
K1 Loop diuretics
K1 Mortality
K1 Prognosis
AB Guidelines recommend down-titration of loop diuretics (LD) once euvolaemia is achieved. In outpatients with heart failure (HF), we investigated LD dose changes in daily cardiology practice, agreement with guideline recommendations, predictors of successful LD down-titration and association between dose changes and outcomes. We included 8130 HF patients from the ESC-EORP Heart Failure Long-Term Registry. Among patients who had dose decreased, successful decrease was defined as the decrease not followed by death, HF hospitalization, New York Heart Association class deterioration, or subsequent increase in LD dose. Mean age was 66 ± 13 years, 71% men, 62% HF with reduced ejection fraction, 19% HF with mid-range ejection fraction, 19% HF with preserved ejection fraction. Median [interquartile range (IQR)] LD dose was 40 (25-80) mg. LD dose was increased in 16%, decreased in 8.3% and unchanged in 76%. Median (IQR) follow-up was 372 (363-419) days. Diuretic dose increase (vs. no change) was associated with HF death [hazard ratio (HR) 1.53, 95% confidence interval (CI) 1.12-2.08; P = 0.008] and nominally with cardiovascular death (HR 1.25, 95% CI 0.96-1.63; P = 0.103). Decrease of diuretic dose (vs. no change) was associated with nominally lower HF (HR 0.59, 95% CI 0.33-1.07; P = 0.083) and cardiovascular mortality (HR 0.62, 95% CI 0.38-1.00; P = 0.052). Among patients who had LD dose decreased, systolic blood pressure [odds ratio (OR) 1.11 per 10 mmHg increase, 95% CI 1.01-1.22; P = 0.032], and absence of (i) sleep apnoea (OR 0.24, 95% CI 0.09-0.69; P = 0.008), (ii) peripheral congestion (OR 0.48, 95% CI 0.29-0.80; P = 0.005), and (iii) moderate/severe mitral regurgitation (OR 0.57, 95% CI 0.37-0.87; P = 0.008) were independently associated with successful decrease. Diuretic dose was unchanged in 76% and decreased in 8.3% of outpatients with chronic HF. LD dose increase was associated with worse outcomes, while the LD dose decrease group showed a trend for better outcomes compared with the no-change group. Higher systolic blood pressure, and absence of (i) sleep apnoea, (ii) peripheral congestion, and (iii) moderate/severe mitral regurgitation were independently associated with successful dose decrease.
YR 2020
FD 2020-04-01
LK https://hdl.handle.net/10668/25921
UL https://hdl.handle.net/10668/25921
LA en
DS RISalud
RD Apr 5, 2025